News Releases
-
Ryvu Therapeutics Presents Preclinical Data on RVU305, ONCO Prime, and Next-Generation ADCs at AACR and ADC Payload Summit -
Ryvu Therapeutics announces dosing of the first patient in the JASPIS-01 Phase II Study of dapolsertib (MEN1703/SEL24) for the Treatment of r/r DLBCL -
Ryvu Therapeutics to present preclinical data on synthetic lethality at the 2025 AACR Annual Meeting
What we do
We challenge current treatment paradigms
At Ryvu, we develop therapeutics that address clinical limitations of current treatments in oncology.
Our pipeline includes candidates with differentiated properties from kinase, synthetic lethality, and immuno-oncology programs.
Investor Relations
Ryvu Therapeutics (Selvita Oncology) was founded in 2007. Since 2014, the company has been listed on Warsaw Stock Exchange under the ticker RVU.
Ryvu Therapeutics is organized for highly efficient R&D driven by breakthrough science, aiming to realize full value potential for its shareholders, partners and employees.
See More
30.80 PLN
-2.69%
RVU • 25/04/2025 17:00 • Warsaw Stock Exchange